Accumulating evidence suggests that protein-bound uraemic toxins play an important role in uraemic complications, especially in cardiovascular disease. Notably, protein-bound uraemic toxins such as indoxyl sulphate, p-cresyl sulphate, and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) have emerged as important targets of therapeutic removal. Indoxyl sulphate stimulates reactive oxygen species production in human umbilical vein endothelial cells (HUVEC) most intensely, followed by CMPF. Indoxyl sulphate and CMPF inhibit cell growth of HUVEC. Haemodialysis (HD) even with a high-flux membrane cannot efficiently remove the protein-bound uraemic toxins because of their high albumin-binding property. Especially, indoxyl sulphate, p-cresyl sulphate, and CMPF showed high protein-binding ratios (more than 95%) and low reduction rates by HD (less than 35%). Removal of indoxyl sulphate and p-cresyl sulphate can be improved to some extent by increasing the diffusion of the free forms with super-flux membrane HD, increasing the dialyzer mass transfer area coefficient and dialysate flow, haemodiafiltration, daily HD, and addition of a sorbent to dialysate. However, CMPF is more strongly bound to albumin (with a binding ratio of 99-100%) than indoxyl sulphate and p-cresyl sulphate, and cannot be removed at all by conventional HD. Uraemic toxins strongly or covalently bound to albumin such that CMPF can be removed by protein-leaking HD. Protein-leaking HD with a polymethylmethacrylate membrane BK-F dialyzer can reduce serum levels of CMPF with improvement of anaemia as well as reduce plasma levels of homocysteine, pentosidine, and inflammatory cytokines.

Keywords:
Protein-leaking haemodialysis, Polymethylmethacrylate, 3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid, Indoxyl sulphate, p-Cresyl sulphate
1.
Vanholder R, De Smet R, Glorieux G, et al: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
2.
Niwa T: Update of uremic toxin research by mass spectrometry. Mass Spectrom Rev 2011;30:510-521.
3.
Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Protein-bound toxins - update 2009. Semin Dial 2009;22:334-339.
4.
Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994;124:96-104.
5.
Niwa T, Ise M, Miyazaki T: Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994;14:207-212.
6.
Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S: The protein metabolite hypothesis, a model for the progression of renal failure: an oral sorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997;62:S23-S28.
7.
Miyazaki T, Ise M, Seo H, Niwa T: Indoxyl sulfate increases the gene expressions of TGF-β1, TIMP-1 and pro-α1(I) collagen in uremic rat kidneys. Kidney Int Suppl 1997;62:S15-S22.
8.
Enomoto A, Takeda M, Tojo A, et al: Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity J Am Soc Nephrol 2002;13:1711-1720.
9.
Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T: Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008;23:1892-1901.
10.
Niwa T: Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 2010;20(suppl 5):S2-S6.
11.
Muteliefu G, Shimizu H, Enomoto A, Nishijima F, Takahashi M, Niwa T: Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21, and prelamin A through oxidative stress. Am J Physiol Cell Physiol 2012;303:C126-C134.
12.
Schepers E, Glorieux G, Vanholder R: The gut: the forgotten organ in uremia? Blood Purif 2010;29:130-136.
13.
Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P: p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1932-1938.
14.
Sakai T, Takadate A, Otagiri M: Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 1995;18:1755-1761.
15.
Aronov PA, Luo FJ, Plummer NS, et al: Colonic contribution to uremic solutes. J Am Soc Nephrol 2011;22:1769-1776.
16.
Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B 2010;878:1662-1668.
17.
Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B 2010;878:2997-3002.
18.
Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T: Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 2012;403:1841-1850.
19.
Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients - protein-bound uremic toxins and endothelial dysfunction. Semin Dial 2011;24:327-337.
20.
Annuk M, Zilmer M, Lind L, Linde T, Fellström B: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001;12:2747-2752.
21.
Dou L, Jourde-Chiche N, Faure V, et al: The uremic solute indoxyl sulphate induces oxidative stress in endothelial cells. J Thromb Haemost 2007;5:1302-1308.
22.
Tumur Z, Niwa T: Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol 2009;29:551-557.
23.
Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T: Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kB activation. Am J Nephrol 2010;31:435-441.
24.
De Smet R, Dhondt A, Eloot S, Galli F, Waterloos MA, Vanholder R: Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 2007;22:2006-2012.
25.
Luo FJ, Patel KP, Marquez IO, Plummer NS, Hostetter TH, Meyer TW: Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis 2009;53:1042-1049.
26.
Krieter DH, Hackl A, Rodriguez A, et al: Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 2010;25:212-218.
27.
Meert N, Eloot S, Waterloos MA, et al: Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009;24:562-570.
28.
Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R: Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002;40:339-347.
29.
Meyer TW, Peattie JW, Miller JD, et al: Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol 2007;18:868-874.
30.
Mabuchi H, Nakahashi H: Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum. Ther Drug Monit 1988;10:261-264.
31.
De Smet R, Vogeleere P, Van Kaer J, Lameire N, Vanholder R: Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. J Chromatogr A 1999;847:141-153.
32.
Mabuchi H, Nakahashi H: Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 1988;49:281-283.
33.
Niwa T, Yazawa T, Maeda K, Kodama T, Uehara Y, Yamada K: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 1990;56:241-245.
34.
Niwa T, Aiuchi T, Nakaya K, Emoto Y, Miyazaki T, Maeda K: Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 1993;39:92-96.
35.
Lim CF, Stockigt JR, Hennemann G: Alterations in hepatocyte uptake and plasma binding of thyroxine in nonthyroidal illness and caloric deprivation. Trends Endocrinol Metab 1995;6:17-20.
36.
Sun H, Frassetto L, Benet LZ: Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006;109:1-11.
37.
Costigan MG, Callaghan CA, Lindup WE: Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 1996;73:169-173.
38.
Sun H, Huang Y, Frassetto L, Benet LZ: Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 2004;32:1239-1246.
39.
Niwa T, Asada H, Tsutsui S, Miyazaki T, Maeda K: Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. Am J Nephrol 1995;15:463-467.
40.
Galli F, Benedetti S, Buoncristiani U, Piroddi, et al: The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 2003;64:748-755.
41.
Galli F, Benedetti S, Floridi A, Canestrari F, Piroddi M, Buoncristiani E, Buoncristiani U: Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 2005;67:750-759.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.